The frequency and management of asparaginase‐related thrombosis in paediatric and adult patients with acute lymphoblastic leukaemia treated on Dana‐Farber Cancer Institute consortium protocols

No abstract is available for this paper.

• Publication year

  2011

• Venue

  British Journal of Haematology

• Publication date

  2011-02-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1111/j.1365-2141.2010.08524.xPMID 21210774PMCID PMC5763913
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Intravenous PEG-asparaginase during remission induction in children and adolescents with newly diagnosed acute lymphoblastic leukemia.

  2010cited by this paper
• Erwinia asparaginase after allergy to E. coli asparaginase in children with acute lymphoblastic leukemia

  2010cited by this paper
• Asparaginase‐related venous thrombosis in UKALL 2003‐ re‐exposure to asparaginase is feasible and safe

  2010cited by this paper
• Thrombosis in childhood acute lymphoblastic leukaemia: epidemiology, aetiology, diagnosis, prevention and treatment.

  2009cited by this paper
• Role of antithrombin concentrate in treatment of hereditary antithrombin deficiency

  2009influential reference
• Long-term results of Dana-Farber Cancer Institute ALL Consortium protocols for children with newly diagnosed acute lymphoblastic leukemia (1985–2000)

  2009cited by this paper
• Venous thromboembolism in patients with acute leukemia: incidence, risk factors, and effect on survival.

  2009cited by this paper
• Comparison of low‐molecular‐weight heparin and antithrombin versus antithrombin alone for the prevention of symptomatic venous thromboembolism in children with acute lymphoblastic leukemia

  2008cited by this paper
• L-Asparaginase and the effect of age on coagulation and fibrinolysis in childhood acute lymphoblastic leukemia

  2008cited by this paper
• Antithrombotic therapy in neonates and children: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).

  2008cited by this paper
• Changes in antithrombin and fibrinogen levels during induction chemotherapy with L-asparaginase in adult patients with acute lymphoblastic leukemia or lymphoblastic lymphoma. Use of supportive coagulation therapy and clinical outcome: the CAPELAL study

  2008cited by this paper
• Favorable outcome for adolescents with acute lymphoblastic leukemia treated on Dana-Farber Cancer Institute Acute Lymphoblastic Leukemia Consortium Protocols.

  2007cited by this paper
• Venous thrombotic complications in adults undergoing induction treatment for acute lymphoblastic leukemia: results from a meta‐analysis

  2007cited by this paper
• Thrombosis and acute lymphoblastic leukaemia

  2007cited by this paper
• Results of the Dana-Farber Cancer Institute ALL Consortium Protocol 95-01 for children with acute lymphoblastic leukemia.

  2007cited by this paper
• A Multicenter Phase II Study Using a Dose Intensified Pediatric Regimen in Adults with Untreated Acute Lymphoblastic Leukemia.

  2006cited by this paper
• Thrombotic complications in childhood acute lymphoblastic leukemia: a meta-analysis of 17 prospective studies comprising 1752 pediatric patients.

  2006cited by this paper
• Comparison of the anticoagulant effect of a direct thrombin inhibitor and a low molecular weight heparin in an acquired antithrombin deficiency in children with acute lymphoblastic leukaemia treated with l‐asparaginase: an in vitro study

  2006cited by this paper
• Developmental haemostasis

  2006cited by this paper
• Thromboembolism in children with acute lymphoblastic leukaemia treated on Dana‐Farber Cancer Institute protocols: effect of age and risk stratification of disease

  2005cited by this paper
• Thromboembolism in Adults with Acute Lymphoblastic Leukemia During Induction with L-Asparaginase-containing Multi-agent Regimens: Incidence, Risk Factors, and Possible Role of Antithrombin

  2004cited by this paper
• Comparison of Escherichia coli-asparaginase with Erwinia-asparaginase in the treatment of childhood lymphoid malignancies: results of a randomized European Organisation for Research and Treatment of Cancer-Children's Leukemia Group phase 3 trial.

  2002cited by this paper
• Improved outcome for children with acute lymphoblastic leukemia: results of Dana-Farber Consortium Protocol 91-01.

  2001cited by this paper
• Thrombotic events revisited in children with acute lymphoblastic leukemia: impact of concomitant Escherichia coli asparaginase/prednisone administration.

  2001cited by this paper
• Bleeding and thrombosis in children with acute lymphoblastic leukaemia, treated according to the ALL-BFM-90 protocol

  1999cited by this paper
• Influence of two different Escherichia coli asparaginase preparations on fibrinolytic proteins in childhood ALL.

  1996cited by this paper
• Changes in coagulation and fibrinolysis in childhood ALL: a two‐step dose reduction of one E. coli asparaginase preparation

  1996cited by this paper
• Hemostasis in Childhood Acute Lymphoblastic Leukemia: Coagulopathy Induced by Disease and Treatment

  1995cited by this paper
• Effects of Erwinia‐asparaginase on the coagulation system

  1995cited by this paper
• Increased endogenous thrombin generation in children with acute lymphoblastic leukemia: risk of thrombotic complications in L'Asparaginase-induced antithrombin III deficiency.

  1994cited by this paper
• Effect of disease and chemotherapy on hemostasis in children with acute lymphoid leukemia.

  1994influential reference
• Acquired antithrombin III deficiency secondary to asparaginase therapy in childhood acute lymphoblastic leukaemia

  1994cited by this paper
• Incidence of thrombotic complications in adult patients with acute lymphoblastic leukaemia receiving L‐asparaginase during induction therapy: A retrospective study

  1992cited by this paper
• A syndrome of thrombosis and hemorrhage complicating L-asparaginase therapy for childhood acute lymphoblastic leukemia.

  1982cited by this paper

• Impact of treatment-induced thrombosis on the prognosis of acute lymphoblastic leukaemia: a protocol for a systematic review and meta-analysis

  2026cites this paper
• Real-World Effectiveness, Safety, and Tolerability of Facilitated Subcutaneous Immunoglobulin 10% in Secondary Immunodeficiency Disease: A Systematic Literature Review

  2025cites this paper
• Safety and efficacy of apixaban thrombosis prevention in pediatric patients with obesity and acute lymphoblastic leukemia

  2025cites this paper
• Prevalence and Risk Factors of L‐Asparaginase‐Related Thrombosis Among Acute Lymphoblastic Lymphoma Patients in a Resource‐Limited Setup of Sub‐Saharan Region

  2025influential citation
• Recognition, prevention, and management of adverse events associated with asparaginase/ pegaspargase treatment of acute lymphoblastic leukemia in adults: consensus of an expert panel

  2025cites this paper
• Incidence and risk factors of venous thromboembolism in patients with acute Leukemia: A systematic review and meta-analysis.

  2025cites this paper
• Real-world analysis of strategies to prevent thrombosis and bleeding in adults with ALL treated with asparaginase

  2025cites this paper
• Catastrophic asparaginase-induced cerebral and systemic thrombosis in a young female with T-cell lymphoblastic lymphoma: A case report & literature review.

  2025cites this paper
• Extracellular Vesicles Drive Coagulopathy Across Hematologic Cancers

  2025cites this paper
• Clinical and germline risk factors for multiple treatment-related toxicities in pediatric acute lymphoblastic leukemia.

  2025cites this paper
• Emerging advancements to improve L-asparaginase-based therapy: New insight into old paradigm, a review.

  2025cites this paper
• Leukemia and risk of stroke: a Mendelian randomization analysis

  2025cites this paper
• Single-Sample, Multiomic Mass Spectrometry for Investigating Drug Effects and Mechanisms.

  2025cites this paper
• Molecular signatures associated with venous thromboembolism in children with acute lymphoblastic leukemia.

  2024cites this paper
• Thromboprophylaxis with intermediate dose enoxaparin during asparaginase containing induction for young adults with acute lymphoblastic leukemia

  2024cites this paper
• New Insights Into Infections’ Risk of Adolescents and Young Adults Treated for Acute Lymphoblastic Leukemia

  2024cites this paper
• Venous thromboembolism in adolescents and young adults with acute lymphoblastic leukemia treated on a pediatric-inspired regimen

  2024cites this paper
• Development and validation of thromboembolism diagnostic algorithms in children with cancer from real-world data

  2024cites this paper
• Medical complications among acute leukaemia patients receiving inward induction chemotherapy at haematooncology section of the National Cancer Institute, Sri Lanka

  2024cites this paper
• Recombinant Erwinia asparaginase (JZP458) in ALL/LBL: complete follow-up of the Children’s Oncology Group AALL1931 study

  2024cites this paper
• Risk factors and clinical impact of thrombosis during induction chemotherapy for pediatric acute lymphoblastic leukemia: A report from CYP‐C

  2024cites this paper
• Underlying Mechanisms of Thrombosis Associated with Cancer and Anticancer Therapies

  2024cites this paper
• Successful treatment of acute lymphoblastic leukemia (ALL) during pregnancy using a pediatric-based protocol incorporating pegylated asparaginase

  2023cites this paper
• IL16 and factor V gene variations are associated with asparaginase-related thrombosis in childhood acute lymphoblastic leukemia patients.

  2023cites this paper
• Overview of venous thromboembolism (VTE) in patients with haematological malignancy

  2023cites this paper
• Incidence and Management of Thromboembolism in Patients with Acute Leukemia

  2023cites this paper
• Impact of pegaspargase dose capping on incidence of pegaspargase-related adverse events in adults

  2023cites this paper
• Asparaginase toxicity in Hispanic adult and pediatric patients with acute lymphoblastic leukemia: current understanding

  2023cites this paper
• Diagnostic and Therapeutic Challenges of Concurrent Intracranial Hemorrhage and Cerebral Venous Thrombosis in a Patient With Acute Lymphoblastic Leukemia: A Case Report and Literature Review

  2023influential citation
• Central nervous system thrombosis in pediatric acute lymphoblastic leukemia in Turkey: A multicenter study

  2023cites this paper
• Comments on "Analysis of risk factors for venous thromboembolism in 76 patients with acute leukemia".

  2023cites this paper
• How I treat pediatric venous thromboembolism in the DOAC era

  2023cites this paper
• Superior sagittal sinus thrombosis in the course of mixed phenotype acute leukaemia treated with acute lymphoblastic leukaemia-like therapy—a case report

  2023influential citation
• Antithrombotic secondary prophylaxis with low dose of apixaban or rivaroxaban in the onco-hematologic patients: comparison with non-neoplastic patients

  2023cites this paper
• Asparaginase therapy in patients with acute lymphoblastic leukemia: expert opinion on use and toxicity management

  2023cites this paper
• Analysis of risk factors for venous thromboembolism in 76 patients with acute leukemia.

  2023cites this paper
• Important Considerations in the Intensive Care Management of Acute Leukemias

  2023cites this paper
• Management of adult acute lymphoblastic leukemia in the Gulf Cooperation Council (GCC) countries: A consensus report from the GCC Adult ALL Working Group

  2023cites this paper
• Effect of BMI on toxicities and survival among adolescents and young adults treated on DFCI Consortium ALL trials

  2023cites this paper
• Antithrombin Therapy: Current State and Future Outlook

  2023cites this paper
• Venous thromboembolism incidence associated with pegylated asparaginase (ASP) compared to the native L‐ASP: A retrospective analysis with an ASP‐based protocol in adult patients with acute lymphoblastic leukaemia

  2023cites this paper
• Current Use of Asparaginase in Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma

  2022cites this paper
• A survey on thromboprophylaxis and coagulation assessment in children and young adults with acute lymphoblastic leukaemia (ALL) in the Nordic and Baltic countries: Different practices of assessment and management

  2022cites this paper
• SOHO State of the Art Updates and Next Questions | Asparaginase-Understanding and Overcoming Toxicities in Adults with ALL.

  2022cites this paper
• Thrombosis and bleeding in hematological malignancy.

  2022cites this paper
• D-dimer and risk for thrombosis in adults with newly diagnosed acute lymphoblastic leukemia

  2022cites this paper
• Asparaginase in the Treatment of Acute Lymphoblastic Leukemia in Adults: Current Evidence and Place in Therapy

  2022cites this paper
• Prospective longitudinal evaluation of treatment-related toxicity and health-related quality of life during the first year of treatment for pediatric acute lymphoblastic leukemia

  2022cites this paper
• BLCTT_A_342052 55..79

  2022cites this paper
• Solving coagulation conundrums: comparing prophylaxis strategies in adult patients receiving PEG-asparaginase

  2022cites this paper
• Thrombosis Complications in Pediatric Acute Lymphoblastic Leukemia: Risk Factors, Management, and Prevention: Is There Any Role for Pharmacologic Prophylaxis?

  2022cites this paper
• Case Report: Genetic Analysis of PEG-Asparaginase Induced Severe Hypertriglyceridemia in an Adult With Acute Lymphoblastic Leukaemia

  2022cites this paper
• Predictors of thrombosis in children receiving therapy for acute lymphoblastic leukemia: Results from Dana‐Farber Cancer Institute ALL Consortium trial 05‐001

  2022cites this paper
• Cardiovascular toxic effects of antitumor agents: Pathogenetic mechanisms.

  2022cites this paper
• Cardio-Oncology Drug Interactions: A Scientific Statement From the American Heart Association

  2022cites this paper
• Hypersensitivity reactions to asparaginase therapy in acute lymphoblastic leukemia: immunology and clinical consequences.

  2022cites this paper
• Challenges in Management of VTE in Children With Cancer: Risk Factors and Treatment Options

  2022cites this paper
• Asparaginase: How to Better Manage Toxicities in Adults

  2022cites this paper
• When Two Maladies Meet: Disease Burden and Pathophysiology of Stroke in Cancer

  2022cites this paper
• The association of age and adverse events of PEG‐asparaginase in a pediatric tertiary care hospital; a retrospective review

  2022cites this paper
• Neurotoxicity Associated with Treatment of Acute Lymphoblastic Leukemia Chemotherapy and Immunotherapy

  2022cites this paper
• Efficacy and Toxicity of Pegaspargase and Calaspargase Pegol in Childhood Acute Lymphoblastic Leukemia: Results of DFCI 11-001

  2021cites this paper
• BLCTT_A_245210 25..40

  2021influential citation
• Anticoagulation treatment and prophylactic edoxaban for cerebral sinus venous thrombosis in an adolescent with acute lymphoblastic leukemia

  2021cites this paper
• Treatment‐induced cerebral sinus venous thrombosis in childhood acute lymphoblastic malignancies: New risk factors to consider

  2021cites this paper
• SOHO State of the Art Updates and Next Questions: Management of Asparaginase Toxicity in Adolescents and Young Adults with Acute Lymphoblastic Leukemia.

  2021cites this paper
• Clinical Utility of Pegaspargase in Children, Adolescents and Young Adult Patients with Acute Lymphoblastic Leukemia: A Review

  2021influential citation
• Thrombosis is associated with worse survival in children with acute lymphoblastic leukemia: A report from CYP‐C

  2021influential citation
• Pegaspargase in Practice: Minimizing Toxicity, Maximizing Benefit

  2021cites this paper
• Optimizing use of L-asparaginase-based treatment of adults with acute lymphoblastic leukemia.

  2021cites this paper
• Molecular mechanisms of hemostasis impairment in oncology

  2021cites this paper
• Increased Toxicity Among Adolescents and Young Adults Compared with Children Hospitalized with Acute Lymphoblastic Leukemia at Children's Hospitals in the United States

  2021cites this paper
• Pulmonary Manifestations of Hematologic and Oncologic Diseases in Children.

  2021cites this paper
• Asparaginase: Understanding and Overcoming Toxicities

  2021cites this paper
• Asparaginase enzyme activity levels and toxicity in childhood acute lymphoblastic leukemia: a NOPHO ALL2008 study

  2021cites this paper
• Venous thromboembolism incidence and risk factors in adults with acute lymphoblastic leukemia treated with and without pegylated E. coli asparaginase-containing regimens

  2021cites this paper
• Central nervous system emergencies in haematological malignancies

  2020cites this paper
• Polygenic risk score-analysis of thromboembolism in patients with acute lymphoblastic leukemia.

  2020cites this paper
• Advances in Supportive Care for Acute Lymphoblastic Leukemia

  2020cites this paper
• Venous thromboembolism following pegaspargase in adults receiving antithrombin supplementation

  2020cites this paper
• Reducing venous thrombosis with antithrombin supplementation in patients undergoing treatment for ALL with Peg-asparaginase-A real world study.

  2020cites this paper
• Impact of exogenous antithrombin on low molecular weight heparin anti‐Xa activity assays in a pediatric and young adult leukemia and lymphoma cohort with variable antithrombin levels

  2020cites this paper
• Direct oral anticoagulants in patients with hematologic malignancies

  2020cites this paper
• Risk prediction for cancer-associated thrombosis in ambulatory patients with cancer: past, present and future.

  2020cites this paper
• A pilot study of procoagulant platelet extracellular vesicles and P-selectin increase during induction treatment in acute lymphoblastic leukaemia paediatric patients: two new biomarkers of thrombogenic risk?

  2020cites this paper
• Quantifying the difference in risk of adverse events by induction treatment regimen in pediatric acute lymphoblastic leukemia

  2020cites this paper
• Optimizing pegylated asparaginase use: An institutional guideline for dosing, monitoring, and management

  2020influential citation
• [Tissue factors and venous thromboembolism in cancer patients].

  2020cites this paper
• Thromboembolism Prophylaxis in Adult Patients with Acute Lymphoblastic Leukemia Treated in the GRAALL-2005 Study.

  2020cites this paper
• Childhood Leukemia

  2020cites this paper
• Anticoagulation prophylaxis reduces venous thromboembolism rate in adult acute lymphoblastic leukaemia treated with asparaginase‐based therapy

  2020cites this paper
• Prevalence and Risk Factors of Adolescent Venous Thromboembolism

  2020cites this paper
• Incidence of venous thrombosis after peg-asparaginase in adolescent and young adults with acute lymphoblastic leukemia

  2020cites this paper
• Risk assessment of venous thromboembolism in hematological cancer patients: a review

  2020cites this paper
• Managing toxicities with asparaginase-based therapies in adult ALL: summary of an ESMO Open–Cancer Horizons roundtable discussion

  2020cites this paper
• The prevention and management of asparaginase‐related venous thromboembolism in adults: Guidance from the SSC on Hemostasis and Malignancy of the ISTH

  2020cites this paper
• Immediate Transfer for Clot Extraction in a Young Woman With Leukemia and Asparaginase-Associated Acute Cerebral Vein Thrombosis

  2020influential citation
• Thromboembolism prophylaxis during L-asparaginase therapy in acute lymphoblastic leukemia - time to reconsider current approaches?

  2020cites this paper
• Neurological complications of pediatric cancer

  2020cites this paper
• Acute Complications and Survival Analysis of Childhood Acute Lymphoblastic Leukemia: A 15-year Experience.

  2020cites this paper